Why Is Regeneron Stock Sinking Monday?

On Friday, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reviewed results from the Phase 3 trial evaluating two dose levels of fianlimab (LAG-3 inhibitor) in combination with Libtayo (cemiplimab) for unresectable locally advanced or metastatic melanoma. Phase 3...